June 1, 2000American Journal of HypertensionOpen Access

Efficacy and safety of omapatrilat in subjects with isolated systolic hypertension

View Full Paper

Ask AI

Bookmark

Why the study?

Does omapatrilat reduce seated systolic blood pressure in subjects with isolated systolic hypertension?

Population

429 subjects with isolated systolic hypertension, mean age 66.7 years.

Comparison

Omapatrilat vs Matching placebo

Design

RCT, randomized, double-blind

Follow-up

9 weeks

Authors

PLPierre LarochelleSouth Dakota School of Mines and Technology

Discussion

Member takes

Implication

Supports omapatrilat for isolated systolic hypertension; confirms efficacy versus placebo in this RCT.

Structured PICO

Does omapatrilat reduce seated systolic blood pressure in subjects with isolated systolic hypertension?

Population

429 subjects with isolated systolic hypertension (seated systolic blood pressure [SeSBP] 160–199 mm Hg and seated diastolic blood pressure [SeDBP] <90 mm Hg), mean age 66.7 years.

Intervention

Omapatrilat (10 mg, 20 mg, or 20 mg increased to 40 mg at week 1)

Comparator

Matching placebo

Outcome

Change from baseline in trough seated systolic blood pressure (SeSBP) at week 9surrogate

Omapatrilat effectively reduces systolic blood pressure in patients with isolated systolic hypertension without adversely affecting orthostatic blood pressure or heart rate.

Cite This Study

Pierre Larochelle (2000) studied this question.

synapsesocial.com/papers/6a81f07e687698565bf20aae https://doi.org/10.1016/s0895-7061(00)00619-1

View Full Paper

Ask AI

Bookmark

Efficacy and safety of omapatrilat in subjects with isolated systolic hypertension

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Efficacy and safety of omapatrilat in subjects with isolated systolic hypertension

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider